Anemia Clinical Trial
Official title:
Improving Iron Status of Children in a Semi-arid Area of Kenya: the Potential of Amaranth Grain Flour
Introduction: Iron deficiency anaemia remains a significant public health challenge.
Localized food based approaches may offer a large opportunity to improve lives and address
the widespread micronutrient deficiencies such as iron in affected households. Viable
solutions where iron rich foods are not readily available may come through diversification
approaches using foods such as amaranth grain reported to contain high iron content and good
quality protein in conjunction with the use of in-home fortification.
Objectives: To determine the efficacy of maize porridge enriched with amaranth flour on
improving diet quality, iron intake and status in children 12-59 months in a semiarid area
in Kenya.
Study population: The study population will comprise children aged 12-59 months in Migwani,
within the larger Mwingi district, Kenya. Mothers or principal caretakers will be
interviewed on behalf of the children. In total, 270 children will be enrolled in the study.
Study design:
The study has a randomized controlled trial design conducted over a period of 4 months/16
weeks.
Treatment/hypothesis: All participating children will be required to take the provided
porridge equivalent to 80g of flour 5 days a week for 16 weeks. There will be 3 treatments
groups as follows; (1) maize porridge enriched with amaranth grain flour at 70:30
maize/amaranth ratio, (2) maize porridge fortified with a multiple micronutrient powder
(MixMe™) and (3) plain maize porridge group. Hypothesis: there will be a significant
difference in hemoglobin and iron status between the three groups.
Methods: Blood samples (5ml) will be collected by veni-puncture at baseline and after
intervention. Hb concentration, Zinc protoporphyrin (ZnPP) and malaria infection will be
assessed in the field. Analyses of serum ferritin, serum transferrin receptor and C-reactive
protein (CRP) will be done at the participating laboratories.
Main study parameter/Endpoints: Change in Hb concentration is the primary outcome of this
study. Body iron measured by serum ferritin (SF) and serum transferrin receptor (STfR) are
the secondary outcome. Iron deficiency will be defined as SF concentration <12 µg/L and
tissue iron deficiency will be defined as serum transferrin receptor concentration of
>8.3mg/L. Infection will be assessed by raised CRP (>10mg/L) as an indicator of acute
inflammation and presence of malaria.
Status | Completed |
Enrollment | 270 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 12 Months to 59 Months |
Eligibility |
Inclusion Criteria: - Aged 12-59 months at the time of entry into the study - Resident in village for at least 6-months and the caretaker plans to remain in the area for the next year - Apparently healthy at the time of entry into the study Exclusion Criteria: - Severe anaemia i.e. Hb concentration <70 g/L (See section 5.5) - Taking iron containing haematinic supplements - Transfused in the last six months - Severely undernourished i.e. anthropometric indices <-3 Z score |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Kenya | Migwani Area | Migwani Area | Mwingi District |
Lead Sponsor | Collaborator |
---|---|
Wageningen University | International Nutrition Foundation (INF), Nestlé Foundation, University of Nairobi |
Kenya,
Hotz C, Gibson RS. Complementary feeding practices and dietary intakes from complementary foods amongst weanlings in rural Malawi. Eur J Clin Nutr. 2001 Oct;55(10):841-9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hemoglobin | Hemoglobin (g/l) | Start of study (T=0), End of study (T=4months) | No |
Secondary | Iron Status | Serum Ferritin microgram/l), serum Transferrin Receptor (mg/l) | Begin (t=0), End of study (t=4 months) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A |